Showing results (101-110 of 119) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2012
Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trialDidier Peiffert, Laetitia Tournier-Rangeard, Jean-Pierre Gérard, et al.Journal of the National Cancer Institute|April 5, 2017
International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12)Joachim Weis, Krzysztof A Tomaszewski, Eva Hammerlid, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2020
Metastatic Pancreatic Cancer: ASCO Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Pelin Cinar, et al.European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETOJean-Yves Blay, Nicolas Penel, Maud Toulmonde, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2Jean-Pierre Gérard, David Azria, Sophie Gourgou-Bourgade, et al.The New England Journal of Medicine|May 13, 2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancerThierry Conroy, Françoise Desseigne, Marc Ychou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2012
Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancerJean-Pierre Gérard, David Azria, Sophie Gourgou-Bourgade, et al.European Journal of Cancer (Oxford, England : 1990)|August 23, 2012
Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2Anne Rullier, Sophie Gourgou-Bourgade, Marta Jarlier, et al.The Lancet. Oncology|April 16, 2021
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean-François Bosset, Pierre-Luc Etienne, et al.The Lancet. Oncology|May 11, 2016
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysisMustafa Suker, Berend R Beumer, Eran Sadot, et al.Pageof 12